ArticleInfectious diseases and therapy2019

Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients.

Essack Mitha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.